Protein that takes care of our DNA is critical to leukaemia cell survival

April 5, 2013
Protein that takes care of our DNA is critical to leukaemia cell survival

A protein – already known to be involved in a cell's response to stress – called Tetratricopeptide repeat domain 5 (TTC5) is critical to the development of acute myeloid leukaemia (AML), according to a new Cancer Research UK study published in Cell Death and Disease.

Scientists at Cancer Research UK's Paterson Institute at The University of Manchester found that reducing the amount of this TTC5 protein in AML cells causes them to die. This research gives a greater understanding of the proteins that cancers need to grow and could help in the development of more targeted drugs in the future.

Normal cells, once they have reproduced about 60 times, automatically kill themselves by a cell death process called apoptosis. It is this mechanism that helps prevent cancer, as older cells that have built up more damage to their DNA are killed off.

, however, are clever and they usually develop the ability to bypass this type of cell death, which means they can carry on dividing and growing.

Dr Tim Somervaille, lead researcher from Cancer Research UK's Paterson Institute at The University of Manchester, said: "In our new study we found that TTC5 represents one of a number of proteins that help keep cells alive. This protein regulates a called , which controls whether genes are turned on or off. Studies like this will increase our understanding of the ways in which leukaemia cells evade death and cause disease."

Dr Julie Sharp, Cancer Research UK's senior manager, said: "Looking at pathways that are often faulty in leukaemia cells can reveal proteins that are helping to fuel the disease,which could help researchers develop new drug treatments. And it's exactly this type of vital research that these and other Manchester scientists will be doing at the new Manchester Cancer Research Centre – bringing together a wide range of expertise to revolutionise ."

Explore further: Scientists find new drug target for hard-to-treat leukaemia

More information: Lynch et al. TTC5 is required to prevent apoptosis of acute myeloid leukemia stem cells, Cell Death and Disease, 2013. doi:10.1038/cddis.2013.107

Related Stories

Scientists find new drug target for hard-to-treat leukaemia

March 30, 2012

(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

Drug's 'double hit' overcomes leukaemia resistance

July 13, 2012

A drug that uses a unique ‘double hit’ to kill leukaemia cells could be a potential new treatment for patients with acute myeloid leukaemia. The research, majority funded by Cancer Research UK, is published this ...

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

Savior of T-cells may be enemy of liver immune cells

April 24, 2017

Researchers at Houston Methodist demonstrated that a surface protein called OX40, responsible for keeping one type of immune system cell alive, can trigger the death of liver immune cells, in turn starting a chain reaction ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.